Introduction {#S0001}
============

Tumor imaging is an indispensable tool during the whole process of treatment. Traditional imaging modalities such as computed tomography (CT),[@CIT0001],[@CIT0002] positron emission tomography (PET),[@CIT0003] FDG-PET/CT,[@CIT0004] and magnetic resonance imaging[@CIT0005]--[@CIT0007] are powerful tools for accurate diagnosis, staging, and visualization of tumors. The emerging of fluorescence imaging, which uses fluorescent molecules for surgical navigation, provides good supplementary to traditional imaging modalities. Optical and fluorescent imaging that aids the maximal tumor excision and minimal collateral damage provides great benefits for the outcomes and quality of life.[@CIT0008]

To date, a variety of fluorescent imaging materials have been used in targeted surgery, including near-infrared fluorescent molecule/complexes,[@CIT0009],[@CIT0010] fluorescent nano-particles,[@CIT0011]--[@CIT0015] and dual-modality PET/fluorescence probe.[@CIT0016] To minimize the off-target effect, the condition activated fluorescent probes have been developed to diminish the background noise, such as pH, enzyme, or redox-responsive probes.[@CIT0017]--[@CIT0021] Self-quenching molecules, which can be turned on after cleavage of the attached quencher by tumor-specific enzymes, are valuable candidates for tumor detection.

Cathepsin B is a tightly regulated cysteine proteinase in normal cells.[@CIT0022] Overproduction of cathepsin B has been found in the initiation, proliferation, angiogenesis, invasion, and metastasis of many carcinomas.[@CIT0023]--[@CIT0025] It is considered as a valuable diagnostic and therapeutic target for cancers and has been widely used in tumor imaging.[@CIT0007],[@CIT0026]--[@CIT0028]

In the present study, a pH-dependent, folate receptor-targeted, and cathepsin B activable CaCO~3~ nanoprobe for in vivo imaging of tumor in mice model was established. [Scheme 1](#SCH0001) shows the design of the CaCO~3~ nanoprobe. The fluorescent probe JF1 was synthesized by conjugating a substrate of cathepsin B using a self-immolative linker. JF1 was then loaded into the folate-PEG modified CaCO~3~ nanoparticles. These nanoparticles are relatively stable at normal physiological pH (7.3) in the blood circulation. After uptake by tumor cells via folate receptor, CaCO~3~ under the acidic pH tumor environment is decomposed quickly to release JF1. After the quencher is cleaved by cathepsin B, the fluorescence of JF2 is thus turned-on under exciting light. The tumor cells can be visualized using a 450 nm LED light source. Scheme 1Schematic of the targeting and activation of JF1. (**A**) Activation of JF1 by cathepsin B. (**B**) In vivo targeting of tumor.

Materials and methods {#S0002}
=====================

Materials and reagents {#S0002-S2001}
----------------------

Folate-PEG and BSA were purchased from Aladdin (Shanghai, People\'s Republic of China). CA-074 was from ApexBio Technology (Houston, TX). DMEM and FBS were from Sijiqing Zhejiang Tianhang Biotechnology (Hangzhou, People\'s Republic of China). Other chemicals were all purchased from Standard commercial sources and were of analytical grade purity.

Chemical synthesis and CaCo~3~ nanoparticle preparation {#S0002-S2002}
-------------------------------------------------------

Synthesis of the fluorescent probe JF1 is schematically shown in [Scheme S1](#SCH0001). Intermediate 1 was prepared according to the literature,[@CIT0028] while Oregon Green 2 was commercially available. Details of synthesis were available in supporting information.

CaCO~3~ nanoparticles were prepared using a modified emulsion method according to the previous reported methods.[@CIT0022],[@CIT0029] Briefly, 7.5 mL of cyclohexane and 1.77 mL Triton X-100 were mixed thoroughly for 10 mins, followed by adding 400 µL mixture of calcium chloride (0.03 M) and compound JF1 (0.01 M). The mixture was agitated vigorously with a magnetic stirrer to form a well-dispersed water-in-oil emulsion. After that, 40 µL of sodium carbonate (0.28 M) was added and mixed under moderate magnetic stirring. After mixing, the above solution was turned to sonication (15 s, 3 times) to form the CaCO~3~ nanoparticles. Nanoparticles were collected by centrifugation at 9,000× *g* for 10 mins and washed with ultrapure water. The pellets were dispersed in 500 μL of PEG water solution (folate-PEG, 3 mg/mL). The folate-PEG modified CaCO~3~ nanoparticles were collected by centrifugation at 9,000× *g* for 10 mins.

Zeta potential of the synthesized CaCO~3~ nanoparticles was measured using a Malvern Zetasizer Nano ZS instrument. Their UV-vis absorption changes were monitored with a UV-visible absorbance spectrophotometer (PerkinElmer Lambda 605S UV/Vis spectrometer) with deionized water as the blank. Scanning electron microscopy (SEM) micrographs were obtained using SEM-Jeol, model: JSM-6360 (Jeol, Germany). The CaCO~3~ nanoparticles were coated with gold using Sputter Coater, model: JFC-1600 (Jeol, Germany).

Release profile of CaCo~3~ nanoprobe under different pH conditions {#S0002-S2003}
------------------------------------------------------------------

The release and lighting-up of fluorescent probe was tested by exposure of CaCO~3~ nanoparticles to PBS (10 mM) with different pH (5.5, 6, 6.5, 7.3). Briefly, cathepsin B was added into 0.5 mL of PBS with a final concentration of 0.6 U/mL. Then, 0.5 mL of 10 µg/mL of CaCO~3~ that suspended in PBS nanoparticles was added. The fluorescence intensity was recorded by UV-vis spectroscopy. To further test the specificity of this probe, 5 µg/mL of CA-074 was added in PBS (PH 5.5) to inhibit the function of cathepsin B.

Cell culture and cell uptake behavior {#S0002-S2004}
-------------------------------------

MCF7 cells purchased from ATCC were cultured in DMEM supplemented with 10% FBS at 37°C and 5% CO~2~. Cells were seeded in 48-well plates. After 24 hrs of incubation, 10 μL of CaCO~3~ nanoparticle solution in DMEM media was added into each well, with a final concentration of 10 μg/mL. Cells were observed at 488 nm after twice washing with DMEM media.

In vivo tumor imaging {#S0002-S2005}
---------------------

Tumor-bearing mice were established by injection 1×10^6^ MCF7 cells into the right flank of nude mice. The mice were used for tumor imaging when tumor volume reached approximately 0.5--1 cm^3^. The mice were anesthetized with 1% pentobarbital sodium (15 mg/kg). Then, 0.1 mg CaCO~3~ nanoparticles in 100 μL PBS were administrated via tail vein injection. Images were analyzed using Living Image 4.3.1 software (Xenogen).

Major organs, including heart, liver, spleen, lung, and kidney, were excised from tumor-bearing mice 1 week after CaCO~3~ nanoparticles injection. Tissue was first washed with PBS and fixed with 4% formaldehyde. It was then embedded in paraffin and sliced into 5 µm thickness sections. The sections were stained with H&E and observed under optical microscope (BX 51, Olympus, Japan).

All animal procedures were approved by the Ethics Committee of the Fifth Affiliated Hospital of Guangzhou Medical University prior to the commencement of the study. Mice were maintained in randomly assigned cohorts in the pathogen-free vivarium with temperature controlled, light cycled rooms of Guangzhou Medical University. All the mice were fed ad libitum. All animal procedures were in compliance with the relevant laws and Institutional Animal Care and Use Committee of the Guangzhou Medical University.

Results and discussion {#S0003}
======================

Characterization of fluorescent probe {#S0003-S2001}
-------------------------------------

The molecular weight of JF1 is confirmed to be 1055.1 Da (Supporting Information). The probe shows an absorption peak at 451 nm and an emission peak at 524 nm ([Figure 1A](#F0001){ref-type="fig"}). The quenched probe (cathepsin B-activable substrate protected) shows weak fluorescence. A 21-fold of fluorescence is restored in 30 mins in the presence of 0.1 U/mL cathepsin B ([Figure 1B](#F0001){ref-type="fig"}). Figure 1Optical characterization of JF1. (**A**). Excitation and emission spectra of JF1. (**B**). Emission spectra of JF1 and JF1 loaded CaCO~3~ nanoparticle under cathepsin (**B**).

Characterization and release profile of fluorescent probe embedded CaCo~3~ nanoparticles {#S0003-S2002}
----------------------------------------------------------------------------------------

CaCO~3~ nanoparticle has a weak negative zeta potential (−4 mV), which decreases to −18 mV after the coating of folate-PEG ([Figure 2A](#F0002){ref-type="fig"}). The average diameter of CaCO~3~ nanoparticles is 200 nm ([Figure 2B](#F0002){ref-type="fig"}). It is interesting that the packaging of probe into CaCO~3~ nanoparticles further reduces its fluorescence background by half ([Figure 1B](#F0001){ref-type="fig"}).Figure 2Characterization and release profile of CaCO~3~ nanoparticles. (**A**). Zeta potential of CaCO~3~ nanoparticles before and after folate-PEG modification. (**B**). Emission spectra of CaCO~3~ nanoparticles under different PH conditions. (**C**). SEM of CaCO~3~ nanoparticles. Scale bar: 200 nm.**Abbreviation:** SEM, scanning electron microscope.

The release and lighting-up of CaCO~3~ nanoprobe were tested by incubating 10 µg/mL CaCO~3~ with 0.3 U/mL cathepsin B at three different pH conditions. As shown in [Figure 2C](#F0002){ref-type="fig"}, fluorescence intensity has a fast rate of increment in the first 8 mins and reaches a plateau in 20--30 mins in a pH 5.5 buffer. The lighting-up of fluorescent probe is relatively slower at higher pH conditions (pH=6, 6.5). CaCO~3~ nanoparticles are stable at pH 7.3 as week fluorescence is detected during the whole experiment.

To further assess the targeting ability, a cathepsin B inhibitor CA-074 was added into the acidic PBS (pH=5.5) to block the lighting-up of JF1. As expected, fluorescence decreased significantly compared to these without CA-074 treatment ([Figure 2C](#F0002){ref-type="fig"}). Therefore, the present nanoprobe can be a good photographic agent for imaging of tumors with overexpression of cathepsin B.

In vitro image of tumor cells {#S0003-S2003}
-----------------------------

Parallel experiments were carried out in MCF7 cells and fibroblast cells. The background fluorescence was very low in the supernatant, which was in accordance with the release profile in PBS. MCF7 cells showed high intensity of fluorescence after 30 mins of incubation. No fluorescence was detected in fibroblast cells after 30 mins of incubation. The fluorescence is very weak in fibroblast cells that have low level of cathepsin B expression after 24 hrs of incubation ([Figure 3](#F0003){ref-type="fig"}). It is noteworthy that the fluorescence localizes in cytoplasm rather than on the cell surface, indicating the successful internalization and dissolution of nanoparticles. Figure 3In vitro imaging of MCF7 cells using CaCO~3~ nanoprobe. The upper row shows MCF7 cells incubated with nanoprobe for 30 mins. The second row shows fibroblast cells incubated with nanoprobe for 24 hrs.

In vivo image of tumor cells {#S0003-S2004}
----------------------------

Nude mice baring MCF7 tumor nodule were injected with CaCO~3~ nanoparticles via tail intravenous injection. Mice were then observed under a Living Image System. Fluorescence was observed in one of the tumor-bearing mice at 5 mins after injection and the intensity increased gradually over time. The tumor was visualized in the other mouse at 10 mins after injection ([Figure 4](#F0004){ref-type="fig"}). The fluorescence intensity was proportional to the tumor load ([Figure S1](#SF0001)). Due to the double "turn-off" ability of the probe, there was no detectable fluorescence in normal tissues ([Figure S2](#SF0002)). Figure 4In vivo imaging of MCF7 baring mice using CaCO~3~ nanoprobe.

The toxicity of nanoparticles is also an important parameter that needs to be analyzed before clinical applications. In the present study, major organs of mice received nanoparticles treatment were subjected to histology analysis. As shown in [Figure 5](#F0005){ref-type="fig"}, no visible pathological change was found in heart, liver, spleen, lung, and kidney in 1 week after treatment. The histology results indicated the good biocompatibility of this probe. However, chronic toxicity tests are still needed to confirm its safety for in vivo applications. Figure 5Histology analysis of heart, liver, spleen, lung, and kidney. No pathological change was observed in these tissues;  20 × magnification.

Conclusion {#S0004}
==========

Since pH decrease is found in most solid tumors due to increased fermentative metabolism and poor perfusion, pH-responsive materials have been developed as a general strategy for tumor targeting.[@CIT0030] CaCO~3~ nanoparticles exhibited promising potential as tumor-targeting carriers owing to its pH-sensitivity and biocompatibility.[@CIT0031] Furthermore, CaCO~3~ nanoparticles can also modulate local pH and inhibit tumor growth in vivo.[@CIT0032]

The results demonstrate that this CaCO~3~ nanoparticle enables fast release of **JF1** into cytoplasm of tumor cells and maintains its intactness in the blood circulation. The release profile is similar to the reported studies, in which CaCO~3~ nanoparticle is used as pH response drug delivery carriers.[@CIT0022],[@CIT0032],[@CIT0033] The protection of probe by nanoparticles can not only lower the signal background by reducing off-target effect, but also delay its clearance from circulation, increasing tumor cell absorption.

In summary, a cathepsin B activable fluorescent probe was synthesized and loaded into CaCO~3~ nanoparticles. This nanoparticle shows good stability in neutral pH condition, and the fluorescence background is very low. The pH-dependent and cathepsin B gated "turn-on" properties of the nanoprobe enable precise and fast indication of tumors both in vitro and in vivo. This strategy of controlled drug release, consistent of pH response (acidic endosome/lysosome), can also be an efficient drug release modality for tumor treatment.
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Supplementary materials {#S0006}
=======================

**Scheme S1**. Synthesis of JF-1.

**Chemical synthesis**

**2-(6-(((2-((((4-(2-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-6-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)amino)hexanamido)benzyl)oxy)carbonyl)(methyl)amino)ethyl)(methyl)carbamoyl)oxy)-2,7-difluoro-3-oxo-3H-xanthen-9-yl)benzoic acid (3).**

To a solution of **1** (132.7 mg, 0.145 mmol) in pyridine (3.0 mL) was added **2** (53.5 mg, 0.145 mmol). The resulting mixture was stirred at room temperature overnight until TLC indicated the reaction was completed. The reaction mixture was diluted with EtOAc and washed with 1N HCl followed by brine. The organic layer was separated and dried over anhydrous MgSO~4~, filtered and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel to give compound **3** (95.3 mg, 52.7%) as a yellow solid. ^1^H NMR (400 MHz, CDCl~3~, δ): 13.58 (1H, brs), 8.05 (1H, d, J = 7.1), 7.76-7.60 (4H, m), 7.40-7.16 (13H, m), 6.93 (2H, m), 6.51-6.40 (2H, m), 5.18-5.03 (4H, m), 4.66 (2H, m), 3.69-3.41 (6H, m), 3.18-2.96 (10H, m), 2.37 (4H, s), 2.03 −1.97 (2H, m), 1.77-1.73 (1H, m), 1.68-1.62 (2H, m), 1.53 (2H, m), 1.02 (6H, d, J = 6.6), 0.95 (6H, s); MS (ESI) m/z: 1247.4 \[M+H\]^+^.

***(Z)-*2-(6-(((2-((((4-(6-amino-2-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)hexanamido)benzyl)oxy)carbonyl)(methyl)amino)ethyl)(methyl)carbamoyl)oxy)-2,7-difluoro-3-hydrazineylidene-3H-xanthen-9-yl)benzoic acid (JF-1).**

To a solution of **3** (95.3 mg, 0.076 mmol) in DMF (2.0 mL) was added 15 μL of hydrazine monohydrate (64--65% solution in water). The reaction mixture was then stirred for 2 hrs at room temperature and monitored by TLC. Upon completion, the solvent was removed under reduced pressure and the crude product was purified by preparative HPLC to afford **JF-1** (23.1 mg, 28.8%) as a yellow solid. ^1^H NMR (400 MHz, CD~3~OD, δ): 7.92 (1H, s), 7.58-7.28 (16H, m), 7.06 (2H, d, J = 16.4), 6.83 (1H, m), 6.46 (1H, d, J = 9.2), 6.32 (1H, d, J = 10.4), 5.05 (4H, d, J = 10.4), 4.49-4.28 (2H, m), 3.65-3.48 (8H, m), 3.00-2.88 (8H, m), 1.78 (1H, d, J = 6.0), 1.57-1.44 (4H, m); ^13^C NMR (125 MHz, CD~3~OD, δ): 175.48, 172.25, 170.01, 156.39, 155.97, 155.26, 154.65, 154.55, 153.38, 143.93, 142.62, 141.95, 138.30, 134.04, 131.89, 129.90, 128.45, 128.39, 128.70, 127.98, 128.60, 128.19, 120.79, 115.03, 115.12, 108.83, 100.62, 67.54, 67.34, 54.03, 53.29, 50.88, 49.02, 40.62, 38.63, 32.43, 32.26,30.49, 27.33, 23.72; MS (ESI): 1055.5\[M+H\]^+^.

**Prepare frozen tissue sections**

Tumor was resected and was used for the preparation of frozen tissue sections immdetaly as in the following: Place the freshly dissected tumor tissue on to a pre-labeled tissue base mold.Cover the entire tissue with cryo-embedding media.Transfer the frozen tissue to a cryotome cryostat to equilibrate the temperature of the tissue.Section the frozen tissue into a 5 µm using the cryotome.Fixation with 75% ethanol and observed under fluorescence microscope.Figure S1The fluorescence intensity of mice with different tumor loads. (**A**). Mouse without tumor shows no fluorescence (left) and tumor-bearing mouse has high fluorescence. (**B**). Fluorescence intensity is higher in larger tumor (middle) than in the smaller ones.Figure S2Frozen section of tumor tissue and adjacent normal tissue. (**A**). Tumor tissue with 20× magnification. (**B**). Tumor tissue with 40× magnification. (**C**). Adjacent normal tissue.
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